<unk>  is a tyrosine Kinase Inhibitor that is FDA approved for the treatment of myelofibrosis and polycythemia vera.   Common adverse reactions include bruising, dizziness, headache, thrombocytopenia and anemia.
Ruxolitinib
Ibrutinib
Bosutinib
Ranibizumab
Ceritinib
Acalabrutinib
Erdafitinib
Gilteritinib